CUREVAC NV (5CV.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:5CV - NL0015436031 - Common Stock
5CV.DE Key Statistics, Chart & Performance
The current stock price of 5CV.DE is 3.892 EUR. In the past month the price decreased by -12.97%. In the past year, price decreased by -8.77%.
5CV.DE Technical Analysis
5CV.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE. 5CV.DE has only an average score on both its financial health and profitability.
5CV.DE Financial Highlights
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -247.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 182.11% | ||
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.03 |
5CV.DE Forecast & Estimates
11 analysts have analysed 5CV.DE and the average price target is 4.02 EUR. This implies a price increase of 3.22% is expected in the next year compared to the current price of 3.892.
For the next year, analysts expect an EPS growth of -163.99% and a revenue growth -84.14% for 5CV.DE
5CV.DE Ownership
5CV.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 64.82 | 42.92B | ||
| 1AE.DE | ARGENX SE | 64.86 | 42.73B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 22.67B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.03B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.02B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.92B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.91B | ||
| IVA.PA | INVENTIVA SA | N/A | 1.09B | ||
| 6IV.DE | INVENTIVA SA | N/A | 967.31M | ||
| NANO.PA | NANOBIOTIX | N/A | 891.02M | ||
| PHIL.MI | PHILOGEN SPA | 19.12 | 637.43M | ||
| FYB.DE | FORMYCON AG | N/A | 424.96M |
Related stock screener links
About 5CV.DE
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 904
Phone: 49707198830
CUREVAC NV / 5CV.DE FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
What is the stock price of CUREVAC NV today?
The current stock price of 5CV.DE is 3.892 EUR. The price increased by 0.36% in the last trading session.
What is the dividend status of CUREVAC NV?
5CV.DE does not pay a dividend.
What is the ChartMill rating of CUREVAC NV stock?
5CV.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does CUREVAC NV belong to?
CUREVAC NV (5CV.DE) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for 5CV stock?
CUREVAC NV (5CV.DE) currently has 904 employees.
Can you provide the market cap for CUREVAC NV?
CUREVAC NV (5CV.DE) has a market capitalization of 876.36M EUR. This makes 5CV.DE a Small Cap stock.